Soligenix Inc (SNGX)

[TruckingAngler]

SNGX get's another $2.6m grant 9/12/2022:
"FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL. 8:34 am ET September 12, 2022.
New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryteT treatment, including at-home usage. The FDA's support will give patients an opportunity to access Soligenix's HyBryteT therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer.
GLTA